PASSAGE BIO, INC. Operating Lease Cost
PASSAGE BIO, INC. (PASG) reported Operating Lease Cost of $105.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-09-03
- PASSAGE BIO, INC. operating lease, cost for the quarter ending 2026-06-30 was $105.00K, a 88.03% decline year-over-year.
- PASSAGE BIO, INC. operating lease, cost for the quarter ending 2026-03-31 was $476.00K, a 45.91% decline year-over-year.
- PASSAGE BIO, INC. operating lease, cost for the quarter ending 2025-12-31 was $791.00K, a 8.13% decline year-over-year.
- PASSAGE BIO, INC. operating lease, cost for the quarter ending 2025-09-30 was $871.00K, a 3.65% decline year-over-year.
- PASSAGE BIO, INC. operating lease, cost for fiscal 2023 was $3.32M, a 0.18% increase from fiscal 2022.
- PASSAGE BIO, INC. operating lease, cost for fiscal 2022 was $3.32M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $105.00K S-4/A · filed 2026-09-03 | $581.00K S-4/A · filed 2026-09-03 | $1.37M derived: sum of 3 quarters · filed 2026-09-03 | $2.24M derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | $476.00K S-4 · filed 2026-07-21 | $1.27M derived: sum of 2 quarters · filed 2026-09-03 | $2.14M derived: sum of 3 quarters · filed 2026-09-03 | $3.02M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | $791.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $1.66M derived: sum of 2 quarters · filed 2026-09-03 | $2.54M derived: sum of 3 quarters · filed 2026-09-03 | $3.42M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $871.00K 10-Q · filed 2025-11-10 | $1.75M derived: sum of 2 quarters · filed 2026-09-03 | $2.63M 10-Q · filed 2025-11-10 | $3.49M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $877.00K S-4/A · filed 2026-09-03 | $1.76M S-4/A · filed 2026-09-03 | $2.62M derived: sum of 3 quarters · filed 2026-09-03 | $3.52M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | $880.00K S-4 · filed 2026-07-21 | $1.74M derived: sum of 2 quarters · filed 2026-09-03 | $2.65M derived: sum of 3 quarters · filed 2026-09-03 | $3.55M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | $861.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $1.76M derived: sum of 2 quarters · filed 2026-09-03 | $2.67M derived: sum of 3 quarters · filed 2026-09-03 | $3.50M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $904.00K 10-Q · filed 2025-11-10 | $1.81M derived: sum of 2 quarters · filed 2025-11-10 | $2.64M 10-Q · filed 2025-11-10 | $3.47M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $909.00K 10-Q · filed 2025-08-12 | $1.74M 10-Q · filed 2025-08-12 | $2.57M derived: sum of 3 quarters · filed 2025-08-12 | $3.40M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $831.00K 10-Q · filed 2025-05-13 | $1.66M derived: sum of 2 quarters · filed 2025-05-13 | $2.49M derived: sum of 3 quarters · filed 2025-05-13 | $3.32M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $830.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.66M derived: sum of 2 quarters · filed 2025-03-04 | $2.49M derived: sum of 3 quarters · filed 2025-03-04 | $3.32M 10-K · filed 2025-03-04 |
| 2023-09-30 | $831.00K 10-Q · filed 2024-11-13 | $1.66M derived: sum of 2 quarters · filed 2024-11-13 | $2.49M 10-Q · filed 2024-11-13 | $3.32M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $830.00K 10-Q · filed 2024-08-08 | $1.66M 10-Q · filed 2024-08-08 | $2.49M derived: sum of 3 quarters · filed 2024-08-08 | $3.32M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $831.00K 10-Q · filed 2024-05-14 | $1.66M derived: sum of 2 quarters · filed 2024-05-14 | $2.49M derived: sum of 3 quarters · filed 2024-05-14 | $3.32M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $1.66M derived: sum of 2 quarters · filed 2024-03-04 | $2.49M derived: sum of 3 quarters · filed 2024-03-04 | $3.32M 10-K · filed 2024-03-04 |
| 2022-09-30 | $829.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.66M derived: sum of 2 quarters · filed 2022-11-10 | $2.49M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $829.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.66M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $829.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |